Exploiting the power of engineered cytokines to develop safe and effective treatments for serious diseases
Anaveon develops biologics that modulate cytokine functionality for immune dysfunction diseases. Founded in 2017 based on IP from the University of Zurich and Novartis, Anaveon’s initial funding came from BaseLaunch. In 2018, Anaveon raised seed financing from the University of Zurich’s Life Sciences fund and in 2019 completed a USD $36.5M Series A from Syncona and Novartis Ventures.
In 2021, Anaveon raised CHF110M in Series B financing, led by Forbion, corner-stoned by Syncona, and joined by Novartis Venture Fund, Cowen Healthcare Investments (a division of Cowen Investment Management), Pfizer Ventures, and Pontifax.
”BaseLaunch provided us with the initial funding to help de-risk our science. But BaseLaunch is actually so much more than just the money – their advice, expertise and network was just tremendously useful in helping us get off the ground.Andreas KatopodisCo-Founder and Chief Executive Officer